Scarica l'app Stockscreener
24.69
0.52%
-0.13
Dopo l'orario di chiusura:
24.76
0.07
+0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Precedente Chiudi:
$24.82
Aprire:
$24.54
Volume 24 ore:
616.05K
Relative Volume:
0.52
Capitalizzazione di mercato:
$3.02B
Reddito:
$588.99M
Utile/perdita netta:
$214.33M
Rapporto P/E:
14.66
EPS:
1.6844
Flusso di cassa netto:
$208.61M
1 W Prestazione:
+1.81%
1M Prestazione:
+3.39%
6M Prestazione:
+18.47%
1 anno Prestazione:
+0.94%
Intervallo 1D:
$24.38
$24.79
Intervallo di 1 settimana:
$23.05
$25.14
Portata 52W:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Nome
Catalyst Pharmaceuticals Inc
Settore
Industria
Telefono
(305) 529-2522
Indirizzo
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
24.69 | 3.02B | 588.99M | 214.33M | 208.61M | 1.6844 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-03-14 | Iniziato | Citigroup | Buy |
| 2024-03-07 | Iniziato | BofA Securities | Buy |
| 2023-12-21 | Iniziato | Oppenheimer | Outperform |
| 2022-08-24 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Ripresa | Piper Jaffray | Overweight |
| 2016-10-05 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Reiterato | ROTH Capital | Buy |
| 2014-09-16 | Reiterato | ROTH Capital | Buy |
| 2014-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2013-10-21 | Reiterato | Aegis Capital | Buy |
| 2013-09-24 | Iniziato | Maxim Group | Buy |
| 2013-09-06 | Reiterato | Aegis Capital | Buy |
| 2013-04-18 | Iniziato | Aegis Capital | Buy |
| 2012-08-27 | Aggiornamento | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Aggiornamento | Merriman | Sell → Neutral |
| 2009-05-29 | Downgrade | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Iniziato | Merriman Curhan Ford | Buy |
| 2007-11-28 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Iniziato | Stifel Nicolaus | Buy |
| 2007-01-05 | Iniziato | First Albany | Buy |
Mostra tutto
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
Catalyst Pharmaceuticals, Inc. (CPRX) stock price, news, quote and history - Yahoo Finance UK
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is It Too Late To Consider Catalyst Pharmaceuticals (CPRX) After Strong Multi Year Rerating? - sahmcapital.com
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study - TradingView
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - TradingView
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Catalyst Pharmaceuticals (CPRX) Still Attractively Priced After Recent Share Price Stability? - Yahoo Finance
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView
JPMorgan Chase & Co. Sells 54,915 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
New Strong Buy Stocks for March 31st - Yahoo Finance Singapore
Best Value Stocks to Buy for March 31st - Yahoo Finance Singapore
Aug Movers: Can Catalyst Pharmaceuticals Inc stock outperform in a bear marketEarnings Recap Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Trading And DCF Upside Signals - Yahoo Finance
Aug Mood: Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Market Sentiment & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Mixed Long Term And Recent Shareholder Returns - Sahm
Insider Buy: Is Catalyst Pharmaceuticals Inc currently under institutional pressure2026 Fundamental Recap & Long-Term Investment Growth Plans - baoquankhu1.vn
Total Market Plus Equity Portfolio's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Analysts see big upside in Catalyst Pharmaceuticals, Inc. (CPRX) - MSN
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes - TradingView
Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of "Strong Buy" by Brokerages - MarketBeat
Vanguard realigns reporting; Catalyst Pharmaceuticals (CPRX) shows 0% ownership - Stock Titan
Truist Financial Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to "Strong-Buy" - MarketBeat
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data - TradingView
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Forecasts - Yahoo Finance
Retail Trends: Does Catalyst Pharmaceuticals Inc align with a passive investing strategy2026 Market WrapUp & Low Drawdown Momentum Ideas - baoquankhu1.vn
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study - TradingView
CPRX Technical Analysis | Trend, Signals & Chart Patterns | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer - TradingView
Will Catalyst Pharmaceuticals Inc benefit from government policyWeekly Loss Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Is Catalyst Pharmaceuticals Inc a momentum stock2026 Growth vs Value & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum Cooldown - Sahm
Why Catalyst Pharmaceutical (CPRX) is a top value stock for the long term - MSN
CPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance Australia
Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Risk Factors & Daily Volume Surge Signals - baoquankhu1.vn
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Patent trial on Catalyst (NASDAQ: CPRX) FIRDAPSE® patents delayed to May 18, 2026 - Stock Titan
Catalyst Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Stock Listing on NASDAQ - Minichart
Catalyst Pharma Patent Trial Against Hetero USA Delayed - TipRanks
Catalyst Pharmaceuticals IncDistrict court delays bench trial to May 18, 2026SEC filing - marketscreener.com
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals (NASDAQ: CPRX) FIRDAPSE patent trial pushed to May 2026 - Stock Titan
Catalyst Pharmaceuticals (CPRX) reports record Q4 and full year 2025 results - MSN
Catalyst Pharmaceuticals, Inc. (CPRX): A bull case theory - MSN
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why - TradingView
Analyst Upgrade: Is Catalyst Pharmaceuticals Inc a defensive stock2026 Macro Moves & Scalable Portfolio Growth Methods - baoquankhu1.vn
Catalyst Pharmaceuticals Inc Azioni (CPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Catalyst Pharmaceuticals Inc Azioni (CPRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Harper Molly | Director |
Dec 12 '25 |
Sale |
23.25 |
26,746 |
621,920 |
2,360 |
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):